# Brookline Venture Partners

> Brookline Venture Partners is a VC fund backing Security and Software. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 7
- Last investment: Apr 2019
- Lead investor: 29%
- Last updated: Aug 2026
- Website: http://www.brooklineventures.com

Brookline Venture Partners is a VC fund in Cambridge focused on Security and Software. Brookline Venture Partners was founded in 2004 to invest in early-stage companies. Its founders are entrepreneurs with operational, financial, and sales experience. BVP partners Ken Levine and Mark Goodman bring a wealth of experience to their portfolio companies, providing strategic and tactical advice to management teams as they navigate thenumerous challenges facing start-up companies.

## Contacts

5 contacts available for Brookline Venture Partners. Shizune tracks 1 team members at Brookline Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/brookline-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Security | 2 | 29% |
| Software | 2 | 29% |
| Enterprise Software | 2 | 29% |
| SaaS | 1 | 14% |
| Health Care | 1 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 29% |
| Series A | 1 | 14% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |
| Funding Round | 1 | 14% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kenneth Levine | Co-founder and Partner | 2 | https://shizune.co/investors/profile/kenneth-levine |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Digital Guardian | Digital Guardian provides the industry’s only data protection platform that is purpose-built to stop data theft from both insiders and external adversaries. The Digital Guardian Data Protection Platform performs across the corporate network, traditional endpoints, and cloud applications. It's buttressed by the DG Cloud, a big data securityanalytics backend that sees and blocks all threats to sensitive information. For more than 15 years, it has enabled data-rich organizations to protect their most valuable assets with a choice of on premises, SaaS or managed service deployment. Digital Guardian’s unique data awareness, combined with threat detection and response, enables organizations to protect data without slowing the pace of their business.It was founded in 2003 and is headquartered in Waltham, Massachusetts, United States. | $30M | Private Equity | Apr 24, 2019 |  |
| TRACON Pharmaceuticals | TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 smallmolecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States. | $27M | Series B | Sep 22, 2014 |  |
| TRACON Pharmaceuticals | TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 smallmolecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States. | $14M | Series A | Apr 20, 2011 |  |
| NitroSecurity | NitroSecurity is a supplier of Unified Information Security solutions that provide Edge-to-Core network security for enterprises across many vertical markets, including healthcare, education, financial services, government, retail, hospitality, and managed services. Leveraging patented data management technology, NitroSecurity delivers anintegrated, cost effective network security product suite for security information & event management, log management, database activity monitoring, network analysis and intrusion prevention. | $6M |  | Oct 11, 2010 |  |
| NitroSecurity | NitroSecurity is a supplier of Unified Information Security solutions that provide Edge-to-Core network security for enterprises across many vertical markets, including healthcare, education, financial services, government, retail, hospitality, and managed services. Leveraging patented data management technology, NitroSecurity delivers anintegrated, cost effective network security product suite for security information & event management, log management, database activity monitoring, network analysis and intrusion prevention. | $10M | Series D | Aug 19, 2008 |  |
| NitroSecurity | NitroSecurity is a supplier of Unified Information Security solutions that provide Edge-to-Core network security for enterprises across many vertical markets, including healthcare, education, financial services, government, retail, hospitality, and managed services. Leveraging patented data management technology, NitroSecurity delivers anintegrated, cost effective network security product suite for security information & event management, log management, database activity monitoring, network analysis and intrusion prevention. | $2M | Series C | Sep 27, 2006 |  |
| NitroSecurity | NitroSecurity is a supplier of Unified Information Security solutions that provide Edge-to-Core network security for enterprises across many vertical markets, including healthcare, education, financial services, government, retail, hospitality, and managed services. Leveraging patented data management technology, NitroSecurity delivers anintegrated, cost effective network security product suite for security information & event management, log management, database activity monitoring, network analysis and intrusion prevention. | $6.5M | Series B | Feb 25, 2005 |  |

7 of 7 investments shown.

## Co-investors
- [First Analysis](https://shizune.co/investors/profile/first-analysis) — VC Fund, 4 deals together
- [NewSpring Ventures](https://shizune.co/investors/profile/newspring-ventures) — VC Fund, 2 deals together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 2 deals together
- [Arcus Ventures](https://shizune.co/investors/profile/venture-capital) — VC Fund, 2 deals together
- [BioMed Ventures](https://shizune.co/investors/profile/biomed-ventures) — VC Fund, 1 deal together
- [General Electric Pension Trust](https://shizune.co/investors/profile/general-electric-pension-trust) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Brookline Venture Partners invest in?

Brookline Venture Partners invests primarily in Security, Software and Enterprise Software startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Brookline Venture Partners?

Public channels for Brookline Venture Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Brookline Venture Partners?

The team at Brookline Venture Partners includes Kenneth Levine (Co-founder and Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co